Owlstone Medical, a Cambridge, UK-based company which specializes in Breath Biopsy® for applications in early disease detection and precision medicine, announced a first closing of $27M in its Series E funding.
The round was led by Ventura Capital, joined by Aviva Ventures, Horizons Ventures, and other existing investors. The close also saw completion of the investment from the Gates Foundation.
The company intends to use the funds to support the ongoing development of its proprietary Breath Biopsy® platform and the development and commercialization of novel diagnostic tests and point of care devices.
Led by CEO Billy Boyle, Owlstone Medical is developing a breathalyzer for disease. The Breath Biopsy platform provides biomarker discovery and validation capabilities to support the development of applications in precision medicine for a wide range of other medical conditions. It also allows for early diagnosis when treatments are more effective and more lives can be saved.
OMED Health is the patient-centric brand of Owlstone Medical, and offers non-invasive breath tests and longitudinal monitoring solutions for those suffering with their digestive health.
FinSMEs
15/01/2025